See more : Koyou Rentia Co., Ltd. (7081.T) Income Statement Analysis – Financial Results
Complete financial analysis of Pharmagen, Inc. (PHRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharmagen, Inc., a leading company in the Medical – Distribution industry within the Healthcare sector.
- PepsiCo, Inc. (PEP.DE) Income Statement Analysis – Financial Results
- Surgutneftegas Public Joint Stock Company (SGGD.IL) Income Statement Analysis – Financial Results
- Kawasaki Kisen Kaisha, Ltd. (KAIKY) Income Statement Analysis – Financial Results
- People & Technology Inc. (137400.KQ) Income Statement Analysis – Financial Results
- Mangalam Timber Products Limited (MANGTIMBER.NS) Income Statement Analysis – Financial Results
Pharmagen, Inc. (PHRX)
About Pharmagen, Inc.
Pharmagen, Inc. distributes specialty drugs to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. The company sources and distributes specialty drugs, blood plasma derivatives, specialty products, vaccines, anti-infectives, and hard-to-find pharmaceuticals. It offers plasma derivatives for treating serious medical conditions, such as cancer, hemophilia, rheumatoid arthritis, multiple scleroses, blood disorders, hepatitis, and HIV; and specialty products for treating respiratory, oncology, cardiovascular, and hormonal syndromes. The company also manufactures and distributes health supplements, including Clotamin, a specialized over-the-counter multivitamin dietary supplement for patients on Warfarin. In addition, it sells traditional pharmaceuticals to its distribution customers, such as antibiotics, vaccines, and other oral and injectable pharmaceuticals; and specializes in the formulation of drugs. The company was formerly known as Sunpeaks Ventures, Inc. and changed its name to Pharmagen, Inc. in January 2013. Pharmagen, Inc. is based in Silver Spring, Maryland.
| Metric | 2013 |
|---|---|
| Revenue | 4.81K |
| Cost of Revenue | 1.77K |
| Gross Profit | 3.05K |
| Gross Profit Ratio | 63.27% |
| Research & Development | 0.00 |
| General & Administrative | 3.19K |
| Selling & Marketing | 193.11 |
| SG&A | 5.20K |
| Other Expenses | 0.00 |
| Operating Expenses | 6.04K |
| Cost & Expenses | 7.81K |
| Interest Income | 3.01K |
| Interest Expense | 3.01M |
| Depreciation & Amortization | 99.35 |
| EBITDA | -2.89M |
| EBITDA Ratio | -42.79% |
| Operating Income | -2.16K |
| Operating Income Ratio | -44.86% |
| Total Other Income/Expenses | -6.00M |
| Income Before Tax | -6.00K |
| Income Before Tax Ratio | -124.67% |
| Income Tax Expense | 457.00 |
| Net Income | -6.46K |
| Net Income Ratio | -134.17% |
| EPS | -0.02 |
| EPS Diluted | -0.02 |
| Weighted Avg Shares Out | 383.51K |
| Weighted Avg Shares Out (Dil) | 383.50K |
PharmaDrug Announces Issuance of Debenture Units
PharmaDrug Announces Proposed Issuance of Debenture Units
PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins
Source: https://incomestatements.info
Category: Stock Reports